Literature DB >> 16698997

Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling.

Washington B Cárdenas1, Yueh-Ming Loo, Michael Gale, Amy L Hartman, Christopher R Kimberlin, Luis Martínez-Sobrido, Erica Ollmann Saphire, Christopher F Basler.   

Abstract

The Ebola virus (EBOV) VP35 protein blocks the virus-induced phosphorylation and activation of interferon regulatory factor 3 (IRF-3), a transcription factor critical for the induction of alpha/beta interferon (IFN-alpha/beta) expression. However, the mechanism(s) by which this blockage occurs remains incompletely defined. We now provide evidence that VP35 possesses double-stranded RNA (dsRNA)-binding activity. Specifically, VP35 bound to poly(rI) . poly(rC)-coated Sepharose beads but not control beads. In contrast, two VP35 point mutants, R312A and K309A, were found to be greatly impaired in their dsRNA-binding activity. Competition assays showed that VP35 interacted specifically with poly(rI) . poly(rC), poly(rA) . poly(rU), or in vitro-transcribed dsRNAs derived from EBOV sequences, and not with single-stranded RNAs (ssRNAs) or double-stranded DNA. We then screened wild-type and mutant VP35s for their ability to target different components of the signaling pathways that activate IRF-3. These experiments indicate that VP35 blocks activation of IRF-3 induced by overexpression of RIG-I, a cellular helicase recently implicated in the activation of IRF-3 by either virus or dsRNA. Interestingly, the VP35 mutants impaired for dsRNA binding have a decreased but measurable IFN antagonist activity in these assays. Additionally, wild-type and dsRNA-binding-mutant VP35s were found to have equivalent abilities to inhibit activation of the IFN-beta promoter induced by overexpression of IPS-1, a recently identified signaling molecule downstream of RIG-I, or by overexpression of the IRF-3 kinases IKKepsilon and TBK-1. These data support the hypothesis that dsRNA binding may contribute to VP35 IFN antagonist function. However, additional mechanisms of inhibition, at a point proximal to the IRF-3 kinases, most likely also exist.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16698997      PMCID: PMC1472134          DOI: 10.1128/JVI.02199-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein.

Authors:  J Talon; C M Horvath; R Polley; C F Basler; T Muster; P Palese; A García-Sastre
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

4.  Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon.

Authors:  X Wang; M Li; H Zheng; T Muster; P Palese; A A Beg; A García-Sastre
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein.

Authors:  W Yuan; R M Krug
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

6.  Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein.

Authors:  St Patrick Reid; Washington B Cárdenas; Christopher F Basler
Journal:  Virology       Date:  2005-08-10       Impact factor: 3.616

7.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.

Authors:  Etienne Meylan; Joseph Curran; Kay Hofmann; Darius Moradpour; Marco Binder; Ralf Bartenschlager; Jürg Tschopp
Journal:  Nature       Date:  2005-09-21       Impact factor: 49.962

8.  Induction of the human protein P56 by interferon, double-stranded RNA, or virus infection.

Authors:  J Guo; K L Peters; G C Sen
Journal:  Virology       Date:  2000-02-15       Impact factor: 3.616

9.  Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication.

Authors:  M Bergmann; A Garcia-Sastre; E Carnero; H Pehamberger; K Wolff; P Palese; T Muster
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

10.  IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction.

Authors:  Taro Kawai; Ken Takahashi; Shintaro Sato; Cevayir Coban; Himanshu Kumar; Hiroki Kato; Ken J Ishii; Osamu Takeuchi; Shizuo Akira
Journal:  Nat Immunol       Date:  2005-08-28       Impact factor: 25.606

View more
  227 in total

1.  Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response.

Authors:  Sabine Steidle; Luis Martínez-Sobrido; Markus Mordstein; Stefan Lienenklaus; Adolfo García-Sastre; Peter Stäheli; Georg Kochs
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Clinical aspects of Marburg hemorrhagic fever.

Authors:  Masfique Mehedi; Allison Groseth; Heinz Feldmann; Hideki Ebihara
Journal:  Future Virol       Date:  2011-09       Impact factor: 1.831

Review 3.  Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion.

Authors:  Søren Jensen; Allan Randrup Thomsen
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

4.  The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation.

Authors:  Takeshi Noda; Larissa Kolesnikova; Stephan Becker; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

5.  Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.

Authors:  Kathleen C Prins; Jennifer M Binning; Reed S Shabman; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

6.  Crystallization and preliminary X-ray analysis of Ebola VP35 interferon inhibitory domain mutant proteins.

Authors:  Daisy W Leung; Dominika Borek; Mina Farahbakhsh; Parameshwaran Ramanan; Jay C Nix; Tianjiao Wang; Kathleen C Prins; Zbyszek Otwinowski; Richard B Honzatko; Luke A Helgeson; Christopher F Basler; Gaya K Amarasinghe
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-05-27

7.  Ebolavirus VP35 is a multifunctional virulence factor.

Authors:  Daisy W Leung; Kathleen C Prins; Christopher F Basler; Gaya K Amarasinghe
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

Review 8.  Innate antiviral immune signaling, viral evasion and modulation by HIV-1.

Authors:  Arjun Rustagi; Michael Gale
Journal:  J Mol Biol       Date:  2013-12-08       Impact factor: 5.469

9.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.

Authors:  Rachel L Kaletsky; Joseph R Francica; Caroline Agrawal-Gamse; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

10.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.